Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Hey! Dildos Sale in our Dildos Store!
Popular Articles

New Heart Disease Risk Score Should Be Recommended In The UK, Say Experts
A new score for predicting a person"s risk of heart disease performs better than the existing test and should be recommended for use in the United Kingdom by the National Institute for Health and Clinical Excellence (NICE), say researchers in a paper published on bmj.com.
drugs without prescription
CSL Biotherapies Starts Shipment Of Seasonal Influenza Vaccine For The 2009-2010 Flu Season
CSL Biotherapies, a subsidiary of one of the world"s leading manufacturers of thimerosal-free seasonal influenza vaccine, announced that it has begun shipment of its seasonal influenza virus vaccine to a national network of U.S. distributors for the 2009-2010 season. CSL Biotherapies plans to deliver more than eight million doses of the vaccine, the majority of which will be in single-dose, thimerosal-free, pre-filled syringes.
News of the day
HIV/AIDS Research Efforts Of New York Scientist Featured
The Brook Community Newspapers/Connecticut Post profiled New York researcher Jeffrey Laurence, who "helped at the outset to fully identify" HIV along with French virologist Luc Antoine Montagnier and others. Laurence, now of the Weill Cornell Medical College Laboratory for AIDS Virus Research at the New York Blood Center, in 1984, "published a paper with Montagnier in the New England Journal of Medicine that brought the news that their virus was the cause of AIDS," the article states. Since the discovery Laurence has continued his research seeking to develop a cure or vaccine for the virus, which now includes investigating the role of stem cells. He said, "The technology is too young to try to say we can cure someone of AIDS or of cancer. We need money to know how to engineer, to refine stem cells to be resistant to infection." The article states, "Laurence is pleased however, that President Barack Obama is "kinder on stem cells and is releasing some of the restrictions,"" on stem cell research (Semmes, 7/24).
Diagnostics

Seegene's Seeplex(R) RV Multiplex PCR Tests Prove Effective For The Identification Of The New Influenza A H1N1

Building on its widely distributed multiplex PCR technology platform, Seegene is now providing healthcare systems worldwide with a powerful diagnostic test for effective identification of the new influenza A virus (swine H1N1). The Seeplex® RV Detection* assays provide a wide range of screening capabilities for Influenza A, while simultaneously testing for up to 18 other respiratory viruses in a single multiplex PCR test. During this current influenza A outbreak, Seegene"s RV products using the company"s sequencing primer patch for final confirmation of swine H1N1 are in use by approximately 200 hospitals worldwide including Mexico, Spain and Korea. In a recent direct comparison of commercially available diagnostic tests, Seegene"s multiplex PCR technology returned the best results for screening for new influenza A virus in a trial conducted by the Ontario Agency for Health Protection and Promotion. The Seeplex RV12 ACE Detection with H1N1 primer patch showed 100% specificity and 95% sensitivity in testing for Swine-origin influenza virus (SOIV) in nasopharyngeal specimens. Seegene offers its supplemental H1N1 specific primer in all respiratory virus detection products while the current H1N1 outbreak lasts. By using this additional primer, any suspicious sample can be checked by two-way detecting process -- first detection by Influenza A conserved matrix (M) gene primer, then subsequent or simultaneous detection by new H1N1 specific hemagglutinin (H) gene primer. While the H1N1 virus has been identified as a pandemic strain, healthcare systems around the world do not yet know what impact this pathogen and its variants will have as the regular flu season approaches, and are therefore seeking reliable screening tools to rapidly expand testing capacity. To help prepare health systems for a robust response in the upcoming flu season, Seegene will release a dedicated multiplex PCR test for Flu A sub-typing in September, which is capable of simultaneously detecting the most common subtypes (H1, H3 and H5) seen in the current and past outbreaks. This test will also provide useful information for the proper antiviral drug prescription as there are many reports about antiviral drug resistance in each serotype. * Seeplex RV Detection tests are for research use in US. Seegene


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009